| 项目 | 本报告期 | 本报告期 比上年同 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | 年初至报告期末 | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 345,179,582.58 | -12.17 | 1,188,509,072.63 | 8.73 | | 利润总额 | -79,241,287.34 | -315.69 | -21,198,154.19 | -115.23 | | 归属于上市公司股东的净利润 | -78.508.463.45 | -353.32 | -27,209,818.77 | -123.51 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | -80,209,053.68 | -367.18 | -44.575.434.71 | -140.11 | | 经营活动产生的现金流量净额 | 不适用 | 不适用 | -403,852,005.54 | -1691.43 | | 基本每股收益(元/股) | -0.112 | -354.55 | -0.039 | ...

Core Viewpoint - WanDong Medical has undergone a leadership change with the resignation of Chairman Hu Ziqiang and the election of Ma Chibing as the new chairman, which has led to a slight increase in stock price, indicating market confidence in the new leadership [1][3]. Company Overview - WanDong Medical, established in 1997 and listed on the Shanghai Stock Exchange, specializes in the research, production, sales, and after-sales service of large medical imaging equipment, particularly digital X-ray systems [1]. - The company holds a leading position in the domestic market for digital X-ray photography systems (DR) and is in the first tier for mobile digital X-ray systems [1]. Financial Performance - In 2024, WanDong Medical's medical device business reported a revenue increase of 23.01%, but the cost of sales rose by 33.21%, resulting in a decrease in gross margin by 4.92 percentage points [2]. - The company's revenue from 2021 to 2024 showed fluctuations, with revenues of 11.56 billion, 11.21 billion, 12.37 billion, and 15.24 billion respectively, reflecting a growth rate of 2.14%, -3.02%, 10.3%, and 23.26% [4]. - The net profit for the same period was 1.83 billion, 1.75 billion, 1.89 billion, and 1.57 billion, with growth rates of -16.98%, -4.27%, 7.51%, and -16.54% [4]. Market Strategy - In response to market demands, WanDong Medical is upgrading its products to high-end full-field digital X-ray systems and plans to emphasize the creation of a smart medical ecosystem [2]. - The company is also facing challenges with product delays due to increased customer expectations and competition from new products in the market [3]. Shareholder Structure - Midea Group is the controlling shareholder of WanDong Medical, holding 45.46% of the shares, and has been involved in the company's management since 2021 [4].